Bavituximab

巴韦妥昔单抗

Report date: 2024/04/10 16:08:22

Base Information

Drug NameBavituximab
Drug Alias Namebavituximab巴维昔单抗Anti-phosphatidylserine monoclonal antibody 3G4Anti-phospholipid monoclonal antibody 3G4Monoclonal antibody 3G4 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-PhosphatidylserineAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAngiogenesis inhibitors
TargetsPhosphatidylserine
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAvid Bioservices IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAvid Bioservices IncUniversity Of Maryland, BaltimoreOncXerna Theraputics Inc
Inactive CompaniesUniversity of Texas Southwestern Medical CenterH Lee Moffitt Cancer Center & Research Institute
Active IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Squamous Cell +[4] 
Inactive IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG